申请人:Takeda Pharmaceutical Company Limited
公开号:US10017508B2
公开(公告)日:2018-07-10
The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.
The present invention is a compound represented by the formula (1):
wherein each symbol is as described in the specification, or a salt thereof.
本发明提供了一种具有 PDE2A 选择性抑制作用的化合物,该化合物可作为预防或治疗精神分裂症、阿尔茨海默病等的药物。
本发明是一种由式(1)表示的化合物:
其中各符号如说明书所述,或其盐类。